OBJECTIVES: Patient involvement in HTA processes aims to ensure reimbursement decisions consider patients’ specialist knowledge and perspective. Previous research found technologies supported by PGSs were less commonly rejected by the National Institute for Health and Care Excellence (NICE) than those without. This research aimed to investigate whether the presence/absence of a PGS was associated with reimbursement decisions in Scotland and identify factors that may influence the likelihood of PGS inclusion. METHODS: Advice reports published by the Scottish Medicines Consortium (SMC) between January 2013 and May 2016 were searched. For each full submission the presence/absence of a PGS was recorded, as well as the SMC decision, advice publication date, indication and orphan medicine status (SMC definition). The proportions of technologies accepted, accepted with restrictions (AWR) and not recommended were compared between reports with and without PGSs using a chi-squared test. RESULTS: Of the 168 reports identified, 123 (73%) included PGSs. PGSs were more commonly included in submissions for orphan compared to non-orphan medicines (42/45 [93%] vs 81/123 [66%]) and with oncology compared to non-oncology indications (40/44 [91%] vs 83/124 [67%]). PGSs were also more commonly included in reports published since January 2015 than before (68/83 [82%] vs 55/85 [65%]). The proportions of submissions that were accepted, AWR and not recommended for use in NHS Scotland were not significantly different between submissions with or without PGSs (49%, 28% and 23% vs 49%, 31% and 20% respectively; X=0.19, p>0.9). CONCLUSIONS: In contrast to findings previously reported for NICE, these results suggest that technologies supported by PGSs are not less commonly rejected by the SMC than those without. Although quantifying the impact of patient input on HTA decision making is not straightforward due to the presence of many confounding influences, further efforts may be needed to understand the influence of PGSs on SMC decision-making.